A 2025 review of 58 trials finds modest cognitive gains, with clear caveats.
Standard cognitive screening thresholds may exclude many patients with biomarker-confirmed atypical Alzheimer’s disease despite early-stage functional impairment, new data show.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results